Candriam SCA’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-142,745
| Closed | -$2.16M | – | 903 |
|
|
2022
Q3 | $2.16M | Buy |
+142,745
| New | +$1.66M | 0.02% | 566 |
|
|
2022
Q1 | – | Sell |
-151,000
| Closed | -$1.06M | – | 858 |
|
|
2021
Q4 | $1.06M | Buy |
+151,000
| New | +$1.58M | 0.01% | 644 |
|
|
2021
Q2 | – | Sell |
-576,495
| Closed | -$7.48M | – | 947 |
|
|
2021
Q1 | $7.48M | Hold |
576,495
| – | – | 0.06% | 306 |
|
|
2020
Q4 | $7.79M | Sell |
576,495
-15,305
| -3% | -$185K | 0.06% | 314 |
|
|
2020
Q3 | $6.96M | Hold |
591,800
| – | – | 0.07% | 297 |
|
|
2020
Q2 | $8.73M | Sell |
591,800
-78,000
| -12% | -$1.15M | 0.09% | 237 |
|
|
2020
Q1 | $15.8M | Hold |
669,800
| – | – | 0.18% | 136 |
|
|
2019
Q4 | $16.2M | Sell |
669,800
-30,000
| -4% | -$621K | 0.17% | 136 |
|
|
2019
Q3 | $13.4M | Buy |
699,800
+95,000
| +16% | +$2.18M | 0.18% | 133 |
|
|
2019
Q2 | $17.8M | Hold |
604,800
| – | – | 0.22% | 103 |
|
|
2019
Q1 | $28.7M | Buy |
604,800
+126,000
| +26% | +$5.55M | 0.37% | 50 |
|
|
2018
Q4 | $17.3M | Buy |
478,800
+152,000
| +47% | +$7.13M | 0.27% | 80 |
|
|
2018
Q3 | $20.1M | Buy |
326,800
+205,100
| +169% | +$13.2M | 0.27% | 86 |
|
|
2018
Q2 | $8.22M | Buy |
121,700
+42,700
| +54% | +$2.39M | 0.13% | 199 |
|
|
2018
Q1 | $4.29M | Buy |
79,000
+7,000
| +10% | +$392K | 0.07% | 316 |
|
|
2017
Q4 | $4.3M | Buy |
72,000
+13,000
| +22% | +$788K | 0.07% | 294 |
|
|
2017
Q3 | $2.87M | Buy |
59,000
+19,000
| +48% | +$1.04M | 0.05% | 379 |
|
|
2017
Q2 | $2.1M | Buy |
40,000
+10,000
| +33% | +$466K | 0.04% | 453 |
|
|
2017
Q1 | $1.36M | Sell |
30,000
-4,000
| -12% | -$178K | 0.03% | 514 |
|
|
2016
Q4 | $1.29M | Hold |
34,000
| – | – | 0.03% | 469 |
|
|
2016
Q3 | $1.28M | Buy |
+34,000
| New | +$750K | 0.03% | 447 |
|
|
2015
Q2 | – | Sell |
-243,000
| Closed | -$7.62M | – | 670 |
|
|
2015
Q1 | $7.62M | Sell |
243,000
-67,000
| -22% | -$1.94M | 0.15% | 181 |
|
|
2014
Q4 | $9.05M | Buy |
+310,000
| New | +$7.86M | 0.19% | 158 |
|
Candriam SCA's AERI Position: Q4 2022 in Review
Candriam SCA sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 142,745 shares — an estimated $2.16M sold.
Candriam SCA first reported a position in AERI in Q4 2014 and held it in 23 quarters. The position peaked at $28.7M in Q1 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Candriam SCA reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Candriam SCA sold 142,745 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2.16M.
- Candriam SCA first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 23 quarters.
- Candriam SCA's Aerie Pharmaceuticals position peaked at $28.7M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.